TriSalus Life Sciences Reports Q1 2025 Growth Amid Financial Challenges and Increased Net Loss

TriSalus Life Sciences, Inc. (NASDAQ: MTAC) is navigating significant developments and challenges as it reports its financial performance for the first quarter of 2025. The company has undergone a recent merger and is dedicated to oncology-focused medical technologies, particularly for solid tumors.

Positive Aspects:

• Revenue Growth: Revenues for Q1 2025 increased by 42.0% to $9.167 million from $6.457 million in Q1 2024, primarily attributed to higher TriNav sales.
• Gross Profit Improvement: Gross profit rose to $7.672 million with a gross margin of 83.7%, although slightly down from 85.0% last year.
• Cost Control: Research and development expenses decreased significantly by 43.6%, reflecting reduced clinical trial costs for nelitolimod.
• Financing Activities: TriSalus secured $10 million through the OrbiMed Credit Agreement, supporting operational cash flow.
• Private Placement Success: The company raised approximately $22 million from a private placement completed in May 2025.

Negative Aspects:

• Increasing Net Loss: The net loss attributable to common stockholders was $11.1 million in Q1 2025, compared to $14.0 million in Q1 2024, highlighting ongoing financial challenges.
• Operational Cash Burn: Net cash used in operating activities was $4.5 million, down from $10.9 million the previous year, emphasizing ongoing liquidity pressures.
• Mounting Liabilities: Total liabilities rose to $62.995 million, mainly due to increased long-term debt and accrued expenses.
• Material Weaknesses in Controls: The company has identified material weaknesses in its internal controls regarding financial reporting, posing risks for compliance and operational effectiveness.
• Uncertain Future of nelitolimod: The regulatory approval process remains uncertain, and the success of clinical trials is not guaranteed.

Key Financial Statistics from Q1 2025:

• Revenue: $9.167 million
• Gross Profit: $7.672 million
• Operating Loss: $(7.329) million
• Net Loss: $(11.087) million
• Weighted Average Shares Outstanding: 28,527,453
• Cash and Cash Equivalents: $13 million as of March 31, 2025

Conclusion: TriSalus Life Sciences is demonstrating growth potential amidst various challenges. While revenues are increasing and operational costs are decreasing, the company faces significant net losses and current liabilities. Management’s ongoing focus will be on securing additional funding and empowering internal controls as they strategize for future growth in the oncology sector.